Physician profile
Ryan John Edwards
NPI 1619355252
$2,180.18
in general payments reported to CMS, 2019-2025
24 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $405 · 2021: $411 · 2022: $299 · 2023: $236 · 2024: $142 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $681.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $480.57 | 2021-2025 | |
| Pfizer INC. | $429.80 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $306.36 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.14 | 2022-2024 | Jardiance |
| Lilly USA, LLC | $148.10 | 2019-2025 | Zepbound |
| Supernus Pharmaceuticals, INC. | $120.56 | 2022-2025 | Qelbree |
| Intuitive Surgical, INC. | $90.91 | 2023 | Da Vinci Surgical System |
| Novo Nordisk INC | $64.11 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.39 | 2019-2021 | |
| Glaxosmithkline, LLC. | $47.35 | 2019-2020 | |
| Amgen INC. | $31.69 | 2021 | |
| Astellas Pharma US INC | $19.79 | 2019 | |
| Allergan, INC. | $18.07 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.43 | 2021 | |
| Biofire Diagnostics, LLC | $13.04 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomerieux INC | $13.04 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.03 | 2019 | |
| Shire North American Group INC | $12.77 | 2019 | |
| Esperion Therapeutics, INC. | $12.62 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $12.24 | 2021 | |
| Adlon Therapeutics L.P. | $12.03 | 2021 | |
| Abbott Laboratories | $11.59 | 2021 | |
| Corium, LLC | $8.44 | 2024 | Azstarys |
| Sumitomo Pharma America, INC. | $6.11 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.